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The risk of the development of venous throm-
boembolism (VTE) extends for several weeks after
total hip replacement.1-12 Untreated, VTE may
result in pulmonary emboli, the chronic and debili-
tating post-thrombotic syndrome, and even sudden
death. In addition, although VTE remains the most
common reason for emergency readmissions after
total hip replacement surgery (THR),13 most
patients who undergo this procedure receive pro-
phylaxis for a limited period of 7 to 14 days. A sur-
vey conducted among US orthopedic surgeons
revealed that 30% of surgeons discontinue prophy-
laxis when patients become ambulatory and that an
additional 65% limit prophylaxis to the hospitaliza-
tion period.14
For patients who undergo THR, there is contro-
versy regarding the need to extend prophylaxis
beyond hospital discharge. Recent randomized con-
trolled trial results have shown that the continuation
of prophylaxis with low–molecular weight heparins
(LMWHs) for 3 or 4 weeks after hospital discharge
reduces the 1-month rate of venographically con-
firmed postoperative deep vein thrombosis (DVT).9-12
Some investigators do not support such an approach
and limit the use of prophylaxis to the hospitaliza-
tion period.15-18
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Purpose: The purpose of this study was to assess the rate of postoperative deep vein
thrombosis (DVT) as a function of oral anticoagulation therapy after total hip replace-
ment surgery.
Methods: A total of 125 patients completed the study. All the patients received sequential
gradient pneumatic compression over elastic stockings until hospital discharge. In addi-
tion, all the patients underwent postoperative heparin therapy followed by oral warfarin
therapy, adjusted in dose to maintain a goal international normalized ratio (INR) level
of 2.0 to 3.0. Warfarin therapy and compression stockings were continued for 1 month
after surgery. Bilateral duplex scanning was performed 1 and 4 weeks after surgery to
assess the rate of DVT.
Results: Nineteen of the 125 patients had DVT develop (15.2%). Of those thromboses,
six (31.6%) and 13 (68%) were detected 1 week and 1 month after surgery, respectively.
The rate of proximal DVT was 2.4% (3 of 125) 1 week after surgery and rose to 8.2%
(10 of 122) 1 month after surgery. Most DVT cases (64%; 12 of 19) were asymptomatic.
The patients in whom DVT developed had significantly lower INR values during the
second to fourth postoperative weeks than did those patients without thrombosis, and
no differences in INR values were found during the first postoperative week.
Conclusion: The risk of the development of DVT extends beyond hospital discharge in
patients who undergo total hip replacement, despite a regimen of prolonged oral anti-
coagulation therapy. This is particularly true in patients whose INR values did not reach
therapeutic range during the first postoperative month. Therefore, thrombosis prophy-
laxis regimens on the basis of the administration of warfarin should try to maintain INR
values within therapeutic range during the entire first postoperative month to minimize
the incidence of DVT. (J Vasc Surg 1999;30:813-20.)
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The purpose of this study was to assess with
venous duplex scanning (VDS) the rate of DVT at 1
and 4 weeks after THR in a group of patients who
underwent a combined therapy of warfarin and
physical methods for 1 month after surgery.
METHODS
After signing an Institutional Review Board–
approved consent form, 157 patients who were
scheduled for elective primary or revision THR at
the Glenbrook and Evanston Hospitals were includ-
ed in the study. There were 95 female and 62 male
participants, with an average age of 66 ± 11 years
(range, 26 to 93 years). All the THRs were per-
formed by one of the authors (J.C.K.), with general
anesthesia used in 130 cases, epidural anesthesia
used in 10 cases, and spinal anesthesia used in 17
cases. A posterior approach was used in the 145 pri-
mary and the 12 revision arthroplasties. One hun-
dred forty-seven patients underwent placement of
uncemented cup components, 10 received cemented
cup components, 99 received cemented stems, and
58 received uncemented stems.
The patients were properly sized and fitted with
bilateral graduated thigh-length elastic stockings
(TED; Kendall, Mansfield, Mass) at hospital admis-
sion. Sequential gradient pneumatic compression
devices (SCD; Kendall) were applied bilaterally during
the operation. A sterile SCD sleeve was applied to the
operative leg, whereas a standard sleeve was used on
the contralateral limb. Elastic TED stockings were
used underneath the compression SCD sleeves. This
combination of methods was maintained until the
patient was fully ambulatory without assistance.
The patients were administered 5000 IU twice a
day of sodium heparin from the night of surgery until
the prothrombin time was within the aforementioned
range. A 10-mg loading dose of warfarin (Coumadin
Dupont Pharma, Wilmington, Del) was started the
night of surgery, with subsequent dose adjustments to
achieve an international normalized ratio (INR)
between 2.0 and 3.0. Warfarin therapy and TED
stockings were continued for 4 weeks after surgery.
INR levels were measured daily during the hospital
stay, three times during the first week after discharge
and twice a week thereafter for 2 weeks, for a total
prophylactic period of 1 month.
With a high-resolution color scanner (Ultramark
9-HDI, Advanced Technology Laboratories, Bothell,
Wash), bilateral VDS was performed by the same expe-
rienced vascular technologist before surgery and at 1
and 4 weeks after surgery. The patients were placed in
a reverse Trendelenburg position at approximately a
10-degree to a 20-degree angle to examine the com-
mon femoral, superficial femoral, profunda femoral,
and greater saphenous veins. The examination began
at the level of the common femoral vein just below the
inguinal ligament. The distal superficial femoral,
popliteal, and calf veins were examined, when possible,
in a dependent position with legs resting on the oper-
ator’s lap. This maneuver induces vein dilation and
improves vein visualization. If the patient was unable
to sit, the leg was externally rotated and the test was
performed in the supine position. All the veins were
examined in the transverse and longitudinal views.
The abnormal examination criteria that indicated
DVT included: no venous Doppler scan signals
noted with respiration or augmentation maneuvers,
echogenic filled vessel lumen, and the inability to
compress a vein with gentle probe pressure not as
the result of extravascular causes. A minimum of two
criteria was required for the diagnosis of DVT.
Thrombi that extended to the popliteal vein or
above were considered proximal, whereas those clots
that were limited to the calf were considered distal.
Sequential compression was discontinued in
patients whose duplex scan examination results were
positive for DVT. In addition, these patinets with
DVT underwent 3 to 5 days of standard intravenous
heparin therapy at therapuetic doses targeted to
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Table I. Comparison of patients who were excluded and included
Excluded (n = 32) Included (n = 125) P value*
Average age (years) 66.5 ± 11 62.9 ± 12 .4
General anesthesia (n) 26 104 .9
Spinal or epidural anesthesia (n) 6 21 .9
Estimated blood loss (mL) 706 ± 356 669.3 ± 280 .8
Anesthesia time (min) 144 ± 30 134 ± 23 .58
Primary THR (n) 29 115 .9
Cemented cup (n) 1 8 .35
THR, Total hip replacement surgery.
*With c 2 test or Fisher exact test.
reach an activated partial thromboplastin time of 2.0
to 2.5 times control, followed by at least 3 months
of warfarin therapy with a target INR level between
2.0 and 3.0.
A two-tailed Fisher exact test was used to com-
pare proportions, and an independent t test was
used to compare continuous variables. Statistical sig-
nificance was defined as P < .05.
RESULTS
One hundred fifty-seven patients were initially
enrolled in the study and completed the prophylactic
protocol, but 32 patients were excluded from the
analysis because of more than two INR results being
missed during the follow-up period. Accordingly, 125
patients were suitable for analysis. The demographic
characteristics of the patients who were excluded and
included are detailed in Table I, and no significant dif-
ferences were found between the two groups. The
patients were admitted to the hospital for an average
of 8.4 ± 4.2 days, and the average estimated intraop-
erative blood loss was 634 ± 237 mL. No patient suf-
fered major bleeding complications at surgery or dur-
ing the follow-up period that required reoperation or
the withdrawal of the patient from the study. There
were eight minor wound hematomas (6.4%), which
were treated conservatively. The INR values of the
patients with bleeding complications were not signifi-
cantly higher than the INR values of the patients
without bleeding complications. In addition, patients
with adequate anticoagulation therapy did not have
more bleeding complications than did patients with
subtherapeutic anticoagulation therapy.
All the preoperative duplex examination results
were negative for DVT, and the total DVT rate with-
in the first postoperative month was 15.2% (19 of 25).
Sixteen patients had thrombi located in the operated
leg, two patients had thrombi in the contralateral leg,
and one patient had bilateral distal thrombi. Overall,
there were 10 thrombi in the left leg and nine in the
right leg. Pulmonary emboli were suspected of har-
boring in five patients, but lung scanning results con-
firmed the diagnosis of pulmonary embolism in only
one patient (0.08%; 1 of 125). This patient was a 93-
year-old woman with asymptomatic DVT that was
detected on the postoperative scan on the 28th day.
No patients died during the follow-up period. To pre-
vent selection bias, we compared the DVT rate of the
patients who completed the study (15%) with the
DVT rate of those who were excluded from the study
for missing INR values (12.5%), and no significant
differences were found (P = .9).
In regards to time of occurrence and location of
thrombi (Table II), VDS detected DVT in 4.8% (6
of 125) of patients on the scan on the seventh post-
operative day. Of these thrombi, 50% (3 of 6) were
proximal and 50% (3 of 6) were distal. On the
duplex scan at the fourth week, 13 additional cases
of DVT were detected (11%; 13 of 119). Of these
thrombi, 54% (7 of 13) were proximal and 46% (6 of
13) were distal.
Table III describes the overall distribution of
thrombi detected in the study according to whether
a patient was symptomatic or asymptomatic at the
time of DVT diagnosis and whether the DVT was
proximal or distal. Overall, 37% (7 of 19) of the
patients with a thrombus detected on VDS had
symptoms of DVT (swelling, redness, tenderness,
heaviness, or pain), whereas 63% (12 of 19) were
asymptomatic for DVT. Two patients with positive
scan results at 1 week in the calf and common
femoral vein had complete DVT resolution by the
28th day. The other 17 patients with DVT had some
degree of improvement.
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Table II. Summary data on the deep vein thrombosis rate at 1 and 4 weeks after total hip replacement surgery
1st week 4th week (new cases) Overall
Total 4.8% (6 of 125) 10.9% (13 of 119) 15.2% (19 of 125)
Proximal 2.4% (3 of 125) 5.9% (7 of 119) 8.0% (10 of 125)
Distal 2.4% (3 of 125) 5.0% (6 of 119) 7.2% (9 of 125)
Table III. Distribution of deep vein thrombosis
symptoms and location with regard to day of diagnosis
Symptomatic Asymptomatic 
Diagnosis DVT DVT
Day 7 scan 1 of 125 (0.8%) 5 of 125 (4%)
Proximal 1 2
Distal 0 3
Day 28 scan (new cases) 6 of 119 (2.5%) 7 of 119 (7.5%)
Proximal 2 5
Distal 4 2
Overall DVT in 4 weeks 7 of 125 (5.6%) 12 of 125 (9.6%)
Proximal 3 7
Distal 4 5
DVT, Deep vein thrombosis.
Table IV compares the demographic characteris-
tics of the patients who did and did not have DVT
develop. There were no statistically significant dif-
ferences between both groups of patients in regards
to the distribution of age, the type and length of
anesthesia, the estimated blood loss, revision THR,
and the use of cemented components.
The average INR values of patients with and
without postoperative DVT are shown in Fig 1. The
INR values were significantly higher in the patients
without DVT than in the patients with DVT during
the second, third, and fourth postoperative weeks.
During the first week, there were no significant dif-
ferences between the two groups of patients.
The average number of days that were necessary
to achieve an INR of 2.0 or more was 3.15 in the
group without thrombosis and 3.66 in the group of
patients in whom DVT developed (P = .85). Table
V details the proportion of patients with an INR of
2.0 or higher during the 1-month therapy period.
The proportion of patients with a therapeutic (2.0 to
3.0) INR is significantly higher in the patients with-
out DVT as compared with the patients with DVT
after the 10th postoperative day. The proportion of
patients with a therapeutic INR value reached a
maximum on the sixth postoperative day, with a
noticeable proportional reduction on the 10th post-
operative day. This could reflect superior monitoring
of warfarin dosing in the hospital as compared with
after hospital discharge.
Table VI shows the proportion of INR results that
were within therapeutic range (2.0 to 3.0) during
each postoperative week. The proportion of patients
within therapeutic range was significantly higher in
patients without DVT than in patients with DVT dur-
ing the third and fourth postoperative weeks.
DISCUSSION
Patients who undergo THR are exposed to a
high risk of the development of thromboembolic
complications when preventive measures are not
implemented. Although it is generally believed that
most VTE appear during the early postoperative
period, there is growing evidence that VTE fre-
quently occurs after hospital discharge in surgical
patients.9-12,19 This issue has received increasing
attention in recent years at both the International
Consensus Conference on VTE prevention20 and
the fifth American College of Chest Physicians
(ACCP) Consensus Conference.21
Four recent European studies have shown that the
prolonging of anticoagulation therapy with the use of
LMWH for 4 or 5 weeks after THR significantly
reduces the rate of DVT as detected with venogra-
phy.9-12 Bergqvist et al10 have reported a significant
reduction in the proximal DVT rate in patients who
undergo THR from 24% in the group receiving
enoxaparin during hospital stay followed by placebo
to 7% in patients who received enoxaparin for 1
month after surgery. There were two episodes of pul-
monary embolism in the placebo group, and none in
the group receiving prolonged enoxaparin. In a study
with a similar design by Planes et al,11 the total DVT
rate was reduced from 19% to 7% with the prolonging
of the use of enoxaparin for as much as 3 weeks after
discharge. On the other hand, these authors did not
find significant differences regarding the rate of prox-
imal DVT with and without the prolonging of pro-
phylaxis with enoxaparin.
Although the preliminary data on LMWH are
mounting, warfarin therapy is still the preferred
method of postoperative prophylaxis after hospital
discharge for patients who undergo THR because it
has been shown to reduce the incidence of postoper-
ative DVT and fatal pulmonary embolism.5,14,22,24-27
For these reasons, our approach to VTE prophylaxis
consisted of a combination of elastic stockings, inter-
mittent pneumatic compression, and adjusted subcu-
taneous heparin therapy during hospitalization fol-
lowed by oral warfarin therapy extending to 4 weeks
after surgery.
The overall rate of bleeding complications found
in our study was low (6.4%), and, more importantly,
none of the patients had severe enough hemorrhagic
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Fig 1. Mean international normalized ratio (INR) values
in the first four postoperative weeks after total hip replace-
ment surgery. Open circles indicate INR values of patients
with deep vein thrombosis, and solid circles indicate INR
values of patients without deep vein thrombosis.
*P < .05, with t test.
**P < .01, with t test.
problems develop to necessitate blood transfusion or
reoperation. Several studies have reported similar
rates of bleeding problems with the use of warfarin
therapy after THR.27,40,41,44 A number of factors
could be responsible for the low rate of bleeding
complications found in this study. First, preoperative
anticoagulation therapy was not instituted, which
could explain the lack of excessive intraoperative
bleeding. In addition, all the patients underwent
operation by the same highly experienced orthopedic
surgeon (J.C.K.). Lastly, few patients had an INR
level more than 3.5 and none of the patients had an
INR of more than 5. The low prevalence of bleeding
problems in combination with the high rate of DVT
found in this study could reflect an overly conserva-
tive approach to anticoagulation therapy, especially
after the 10th postoperative day, as shown by the
high proportion of patients with subtherapeutic INR
levels. A recent study that compared two regimens of
warfarin therapy found more bleeding complications
with a more aggressive approach consisting of war-
farin therapy beginning 2 weeks before surgery as
compared with the night before surgery.46
The total DVT rate of 15% within the first post-
operative month is concerning because it far exceed-
ed the rate found at discharge (4.8%), which suggests
that an extended prophylaxis protocol was unable to
prevent the development of 13 new thrombi after
hospital discharge. However, it is important to note
that none of the patients had a fatal pulmonary
embolus develop within 1 month after THR and that
the total mortality rate during the study was 0%. In
this regard, recent studies are revealing a low mortal-
ity rate after THR in patients who undergo different
prophylactic methods.22,25,37-39
Because the DVT rate was low initially (4.8%), a
combined prophylactic protocol appears to be effec-
tive during the first week of prophylactic therapy,
especially regarding proximal clots (2.4%). Similar
venographic results confirmed rates that have been
reported at 1 week in patients who undergo therapy
with enoxaparin.28,29 Similarly, Tremaine et al6 fol-
lowed a group of 20 patients who underwent THR
who received LMWH while in the hospital and per-
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Table IV. Comparison of patients with and without DVT
DVT (n = 19) No DVT (n = 106) P value*
Average age (years) 65.8 ± 11 64.2 ± 12 .54
General anesthesia (n) 16 88 .4
Spinal or epidural anesthesia (n) 3 18 .4
Estimated blood loss (mL) 733 ± 292 666.3 ± 298 .33
Anesthesia time (min) 143 ± 25 141 ± 30 .79
Primary THR (n) 18 97 .9
Cemented cup (n) 0 8 .35
DVT, Deep vein thrombosis; THR, total hip replacement surgery.
*With c 2 test or Fisher exact test.
Table VI. Proportion of patients with internation-
al normalized ratio values within therapeutic range
during the first postoperative weeks and duplex
scan outcome
Percent of patients with INR between 2.0 and 3.0
Postoperative week No DVT DVT P value*
First 41% 40% .97
Second 40% 28% .25
Third 61% 27% <.001
Fourth 61% 11% <.001
INR, International normalized ratio; DVT, deep vein thrombosis.
*With c 2 test.
Table V. Comparison of the proportion of
patients with international normalized ratio values
of 2.0 or higher during the first postoperative
month with patients with and without deep vein
thrombosis
Percent of patients with INR > 2 
Postoperative day No DVT DVT P value*
1 0 0 1
2 0 0 1
3 78% 77% .8
5 75% 61% 18
6 83% 76% .5
10 56% 35% .18
14 62% 22% .003
18 63% 22% .002
21 58% 33% .08
25 62% 11% <.01
28 59% 11% <.01
INR, International normalized ratio; DVT, deep vein thrombosis.
*With Fisher exact test.
formed VDS 1 and 3 weeks after surgery. No clots
were found on the 1-week scan, and eight clots
(40%) were found on the 3-week scan, with only two
of these cases with symptoms of DVT.
The high proportion of asymptomatic cases
(36%) detected in this study was surprising. In our
opinion, these results emphasize the value of VDS
after THR to detect asymptomatic proximal clots,
which could cause pulmonary emboli, sudden death,
or the post-thrombotic syndrome. For example,
Ascani et al36 found a 28% DVT rate after THR,
with all cases being asymptomatic. Furthermore,
30% of those asymptomatic thrombi were occluding
the common femoral vein and 45% were considered
proximal.36 Therefore, the clinical follow-up exami-
nation of patients after THR is not accurate for the
diagnosis of DVT, and the long-term impact of
asymptomatic DVT after THR remains to be eluci-
dated in further prospective studies with objective
evaluation of the development of chronic venous
insufficiency.
Similar to other studies, significant differences in
the INR results between patients with and without
DVT during the first postoperative week were not
found in this study.40,41 This might reflect the diffi-
culty in achieving the targeted INR range during the
first days of treatment. A recent study has reported
that 23% of patients who undergo warfarin therapy
have a lower level of anticoagulation than the target
range at the time of hospital discharge.27 If reagents
that are relatively insensitive to depletion of factors
II and X are used, warfarin monitoring on the basis
of the INR may be unreliable during the first days of
treatment.42 The INR values were significantly high-
er during the second to fourth postoperative weeks
in patients in whom VTE did not develop, and there
was a noticeable reduction in the proportion of
patients with INRs of 2.0 or higher after the 10th
postoperative day (Table V). These results suggest
that effective warfarin monitoring and dose adjust-
ment may be more difficult after hospital discharge,
decreasing the overall efficacy of post-discharge
VTE prophylaxis.
Despite the evidence favoring extended prophy-
laxis, some investigators are reluctant to routinely
implement prophylaxis beyond discharge, especially if
a duplex scan examination result is normal before dis-
charge.15-18,23 The role of VTE screening after THR
remains controversial. Ultrasound scanning has limi-
tations for the detection of asymptomatic DVT30,31
and is less accurate than venography for DVT screen-
ing after THR.32 However, high resolution color
duplex scanning performed by experienced personnel
achieves a good sensitivity for the detection of proxi-
mal DVT in these cases and is used by several investi-
gators.8,23,26,33,34 VDS was used in this study because
we did not consider it appropriate to perform two sets
of venograms within 1 month in patients at high risk.
Recent studies showed that more than 20% of veno-
graphic results were considered inadequate, indicating
that the gold standard venogram has its own limita-
tions.28,35 It is important to note that both duplex
ultrasound scanning and venography are coincident in
documenting a significant number of DVT cases that
develop after hospital discharge in many of the afore-
mentioned studies. Lastly, there is also controversy in
regards to which pharmacologic agent should be
instituted for post-discharge prophylaxis. Warfarin
therapy is inexpensive and well accepted by patients,
which makes it an attractive method for VTE preven-
tion after THR. However, the overall cost of the use
of warfarin therapy is increased by the relatively high
DVT rates reported with its use and the need to mon-
itor INR levels for dose adjustments. Some studies
have reported a small reduction in the incidence of
DVT with LMWHs as compared with warfarin, but
LMWHs are associated with more bleeding complica-
tions.40,41,43,44
This study suggests that the combination of phys-
ical methods and unfractionated heparin therapy fol-
lowed by warfarin therapy for 1 month after total hip
arthroplasty can result in a low rate of symptomatic
DVT and pulmonary embolism if a therapeutic level
of anticoagulation therapy is maintained for at least 4
weeks after surgery. However, an overall DVT rate of
15.2% at 1 month after THR, and especially an 8%
proximal DVT rate, are still unacceptably high.
Further prospective and randomized studies are war-
ranted to assess the real advantages of prophylaxis
after hospital discharge and to investigate the best
available, most cost-effective options and the appro-
priate duration of prophylaxis needed to safely treat
patients after total hip arthroplasty.
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Dr Russell D. Hull (Calgary, Alberta, Canada). This
discussion was not rehearsed. I saw the paper, but I did
not see the questions. This is work in progress from a large
double-blind randomized trial that will be reported in
detail at subsequent meetings. It has been reported in
brief at the American Association of Hip and Knee
Replacement Surgeons. This was a study of warfarin sodi-
um administered in the hospital for 6 days as compared
with low–molecular weight heparin therapy where
low–molecular weight heparin was given in close proxim-
ity to the surgery. What was different with the low–mole-
cular weight heparin regimens, and this was with dal-
teparin, was going within 2 hours before surgery, which is
heresy in North America. We did this while going not
closer than 4 hours after surgery (actually an average time
of 6 hours just after surgery), which is quite different from
the 18 to 24 hours or 12 to 24 hours with other regimens.
So, it was dalteparin given very close to surgery versus
warfarin the night of the day of surgery. On day 6, the
proximal rates were 0.8% in the preoperative dalteparin
regimen, 0.8% in the postoperative, and 3% in the war-
farin. The total rates were 10.7%, 13.1%, and 24%. So, the
first question that we have answered is that low–molecular
weight heparin given very close to surgery is more effec-
tive than warfarin sodium given the evening of the day of
surgery. These rates are extraordinarily low, and the regi-
men we used was different to that used traditionally in
North America. I will not pursue that now.
The next issue is whether prophylaxis is needed in
North America. We discharged patients early. There is
strong division in opinion. Many argue that it is not worth
pursuing prophylaxis out of hospital. We anticipated that
we would do better with low–molecular weight heparin
than with warfarin in hospital. We believed that there was
no point in pursuing warfarin out of hospital, so it was
stopped at hospital discharge. The overall rates with
venography are 36%, a proximal deep vein thrombosis rate
of 9.2%. Very close to what you would have predicted.
If you look at the modified regimen with dalteparin,
you will see a proximal rate for pre of 3.1% and a proximal
rate of 2%. These are obviously different with clinical sta-
tistical significance.
So, in answer to your two questions, modifying the
regimen of dalteparin improves the thrombosis rates after
surgery by reducing the proximal thrombosis rate. In hos-
pital and in North America, yes, we need out of hospital
prophylaxis.
Thank you.
DISCUSSION
